详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Hsp90/C terminal Hsc70-interacting protein regulates the stability of Ikaros in acute myeloid leukemia cells

1| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C

作者：

机构： [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp,Sch Med, Fac Basic Med,Chinese Minist Educ,Key Lab Cell Di, Hongqiao Int Inst Med,Chem Biol Div Shanghai Univ, Shanghai 200025, Peoples R China [2]Zhejiang Univ, Affiliated Hosp 2, Dept Ultrasound, Hangzhou 310009, Peoples R China [3]Soochow Univ, Affiliated Hosp 3, Dept Hematol, Changzhou 213003, Jiangsu, Peoples R China [4]Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, Shanghai Inst Hematol,State Key Lab Med Genom,Sch, Shanghai 200025, Peoples R China

出处：

DOI：

ISSN：

关键词： Ikaros CHIP Hsp90 AML STA-9090

摘要：

The stability of Ikaros family zinc finger protein 1 (Ikaros), a critical hematopoietic transcription factor, can be regulated by cereblon (CRBN) ubiquitin ligase stimulated by immunomodulatory drugs in multiple myeloma. However, other stabilization mechanisms of Ikaros have yet to be elucidated. In this study, we show that the pharmacologic inhibition or knockdown of Hsp90 downregulates Ikaros in acute myeloid leukemia (AML) cells. Proteasome inhibitor MG132 but not autophagy inhibitor chloroquine could suppress the Hsp90 inhibitor STA-9090-induced reduction of Ikaros, which is accompanied with the increased ubiquitination of Ikaros. Moreover, Ikaros interacts with E3 ubiquitin-ligase C terminal Hsc70 binding protein (CHIP), which mediates the STA-9090-induced ubiquitination of Ikaros. In addition, the knockdown of Ikaros effectively inhibits the proliferation of leukemia cells, but this phenomenon could be rescued by Ikaros overexpression. Collectively, our findings indicate that the interplay between HSP90 and CHIP regulates the stability of Ikaros in AML cells, which provides a novel strategy for AML treatment through targeting the HSP90/Ikaros/CHIP axis.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 1 区

生物

小类 | 1 区生物学

最新[2023]版：

大类 | 2 区生物学

小类 | 2 区生物学

JCR分区：

出版当年[2019]版：

Q1 BIOLOGY

最新[2023]版：

Q1 BIOLOGY

影响因子： 8 最新[2023版] 7.3 最新五年平均 4.611 出版当年[2019版] 3.549 出版当年五年平均 3.583 出版前一年[2018版] 6.038 出版后一年[2020版]

第一作者：

第一作者机构： [1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp,Sch Med, Fac Basic Med,Chinese Minist Educ,Key Lab Cell Di, Hongqiao Int Inst Med,Chem Biol Div Shanghai Univ, Shanghai 200025, Peoples R China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Donor-derived MDS/AML in families with germline GATA2 mutation [2]Microfluidic organ chip of fluid-solid dynamic curved interface [3]髓系细胞生长因子在急性髓系白血病防治中的作用 [4]Redox metabolism maintains the leukemogenic capacity and drug resistance of AML cells [5]NADPH metabolism determines the leukemogenic capacity and drug resistance of AML cells [6]Construction of a rapid microfluidic-based SNP genotyping (MSG) chip for ancestry inference [7]Identification of Rfx6 target genes involved in pancreas development and insulin translation by ChIP-seq [8]Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells [9]Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells [10]Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)